Navigation Links
Notification of Annual General Meeting and Extraordinary General Meeting
Date:6/11/2008

VALLEY COTTAGE, New York, June 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced a notice convening its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM"). The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30 p.m. Israel time, respectively, on July 17, 2008.

At the AGM it is proposed that:

-- the annual report and financial statements for the year ended December

31, 2007 be received;

-- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the

Company's auditors and the fixing of their remuneration be authorized;

and

-- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy, and Laurence

Charney be re-appointed as Directors of the Company.

At the EGM it is proposed that:

-- the grant of options to Michael Weiss and Ben-Zion Weiner as detailed

in the Notice be approved;

-- the grant of options to Ben-Zion Weiner and William Kennedy as detailed

in the Notice be approved; and

-- the remuneration terms for Laurence Charney as detailed in the Notice

be approved.

The Notice of the AGM and EGM is available for the public at the US Securities Exchange Edgar site: http://www.sec.gov/ and at the Israel Securities Authority's site: http://www.magna.isa.gov.il .

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
2. AMICAS Transforms Critical Results Notification with RadStream
3. Merge Technologies Receives Expected Additional NASDAQ Notification
4. Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price
5. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
6. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
7. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
8. Delisting Notification Received from the American Stock Exchange
9. PreMD Appeals American Stock Exchange Delisting Notification
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Torrance, CA (PRWEB) , ... April 30, 2016 ... ... discussed on Dr. Carol Francis Talk Radio with Hypnotherapist, Mary O'Maley. What ... to help with habit control (substances, smoking, weight control), pain relief (chronic and ...
(Date:4/30/2016)... ... April 30, 2016 , ... The ... , a program to critically evaluate and rank health-focused applications and connected devices ... to provide independent, unbiased and accurate information to help accelerate patient and provider ...
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, ... global impact on public health. The World Veterinary Association (WVA) and the World ... have selected continuing education with a One Health focus, which emphasizes how veterinarians ...
(Date:4/30/2016)... Jamaica (PRWEB) , ... April 30, 2016 , ... ... and Duane Boise, President and CEO of EMED, today signed a multifaceted agreement ... , EMED and the Northern Caribbean University Department of Natural and Applied Sciences, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) ... a minimally invasive procedure performed, when indicated, to correct the partial displacement ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
Breaking Medicine Technology: